Seres Therapeutics, Inc.
MCRB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $351 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $13,352 | $1,059 | $3,527 | $0 |
| Gross Profit | -$13,001 | -$1,059 | -$3,527 | $0 |
| % Margin | -3,704% | – | – | – |
| R&D Expenses | $0 | $12,939 | $11,821 | $12,841 |
| G&A Expenses | $9,476 | $10,253 | $11,888 | $12,462 |
| SG&A Expenses | $9,476 | $10,253 | $11,888 | $12,462 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $630 | $0 | $3,532 |
| Operating Expenses | $9,476 | $23,822 | $23,709 | $28,835 |
| Operating Income | -$22,477 | -$24,881 | -$27,236 | -$28,835 |
| % Margin | -6,403.7% | – | – | – |
| Other Income/Exp. Net | $30,681 | $5,026 | $59,918 | $13,198 |
| Pre-Tax Income | $8,204 | -$19,855 | $32,682 | -$15,637 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $8,204 | -$19,855 | $32,682 | -$15,637 |
| % Margin | 2,337.3% | – | – | – |
| EPS | 0.937 | -2.271 | 3.755 | -1.808 |
| % Growth | 141.2% | -160.5% | 307.7% | – |
| EPS Diluted | 0.935 | -2.271 | 3.75 | -1.808 |
| Weighted Avg Shares Out | 8,759 | 8,744 | 8,703 | 8,650 |
| Weighted Avg Shares Out Dil | 8,772 | 8,744 | 8,715 | 8,650 |
| Supplemental Information | – | – | – | – |
| Interest Income | $618 | $546 | $618 | $437 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,059 | $1,059 | $1,076 | $1,085 |
| EBITDA | $9,263 | -$18,796 | $33,758 | -$14,552 |
| % Margin | 2,639% | – | – | – |